Does Humana Cover Depression Treatment in Maine? A 2026 Guide

Last updated: July 20, 2026

If you have Humana insurance in Maine and need depression treatment, understanding your coverage is an important first step. Humana operates exclusively as a Medicare Advantage (MA) plan in Maine. It exited the commercial insurance market. Which means your depression benefits are governed by federal CMS regulations rather than Maine state parity law. This guide explains what Humana’s Part D formulary may cover for depression medications, how Maine’s Electronic Prescribing of Controlled Substances (EPCS) rules apply, and how to navigate prior authorization, step therapy, and appeals if coverage is denied.

Check if your Humana plan may cover depression treatment through Klarity Health:
Verify your benefits →

Key facts for Humana members in Maine (2026):

• Plan type: Medicare Advantage ONLY. Humana exited the commercial (employer/individual) market in Maine. § 2749-A state parity law does not apply; CMS 42 CFR Part 422 governs.
• PBM: Humana Pharmacy Solutions (HPS) manages Part D prescription drug benefits.
• EPCS: Maine requires EPCS for Schedule II. V controlled substances. Standard antidepressants are non-scheduled. EPCS is entirely inapplicable. Spravato (esketamine nasal spray, Schedule III) = EPCS REQUIRED.
• PA: Generic SSRIs/SNRIs typically Tier 1. 2 with no or minimal PA. Brand antidepressants may require step therapy or PA. Spravato requires specialty PA + REMS program.
• Dual-eligible: Members with both Medicare and MaineCare (Medicaid) have additional coverage coordination rights.
• Key contacts: Humana 1-800-448-6262 / HPS 1-800-379-0092 / Maine Bureau of Insurance 1-800-300-5000

Humana in Maine: Medicare Advantage Only

Humana no longer offers commercial health insurance plans in Maine. All Humana members in the state are enrolled in Medicare Advantage plans, which are regulated by the Centers for Medicare & Medicaid Services (CMS) under 42 CFR Part 422. Not by Maine’s state insurance laws.

This has an important consequence for parity protections: Maine’s mental health parity statute (Me. Rev. Stat. Ann. tit. 24-A, § 2749-A) applies to state-regulated commercial insurance. Because Humana MA plans in Maine are federally regulated, § 2749-A does not apply. Instead, the federal Mental Health Parity and Addiction Equity Act (MHPAEA), as implemented through CMS regulations, governs Humana’s mental health benefits. Including depression treatment coverage.

In practice, CMS requires Medicare Advantage plans to comply with MHPAEA, meaning Humana may not impose more restrictive limits on mental health benefits (including depression treatment) than it applies to comparable medical or surgical benefits. If you believe a coverage decision is inconsistent with parity requirements, you have the right to appeal through the federal Medicare appeals process (described below).

Humana Part D Depression Medication Coverage (HPS Formulary, 2026)

Depression medications are covered under the Part D prescription drug benefit administered by Humana Pharmacy Solutions (HPS). The following table reflects typical HPS formulary placement for commonly prescribed antidepressants. Coverage may vary by specific plan; verify your formulary at the HPS portal or by calling 1-800-379-0092.

Tier placements and PA requirements are subject to change. Verify your specific plan’s formulary at the Humana portal or by calling HPS at 1-800-379-0092.

Maine EPCS Requirements for Depression Medications

Maine has one of the broadest Electronic Prescribing of Controlled Substances (EPCS) mandates in the country, covering Schedule II through Schedule V drugs. For depression treatment, this requirement is relevant only for Spravato. Virtually all other antidepressants are non-scheduled and fall entirely outside Maine’s EPCS rules.

For telehealth patients in Maine, the practical takeaway is clear: the overwhelming majority of depression medications prescribed via telehealth. SSRIs, SNRIs, bupropion, mirtazapine, and similar agents. Are entirely non-scheduled, so Maine’s EPCS requirement poses no barrier. Spravato is the sole exception, but it requires in-office administration under a certified healthcare setting (REMS program), making it unsuitable for telehealth prescribing regardless of EPCS status.

Spravato (Esketamine): A Special Case

Spravato (esketamine nasal spray) is FDA-approved for treatment-resistant depression (TRD) and major depressive disorder with acute suicidal ideation (MDSI). It is the only antidepressant classified as a controlled substance (Schedule III) and therefore the only depression medication subject to Maine’s EPCS mandate.

Under HPS Part D, Spravato typically requires:

• Prior authorization: Documentation of 2 or more adequate antidepressant trials at therapeutic doses for sufficient duration, with inadequate response.
• REMS program: Spravato is subject to a Risk Evaluation and Mitigation Strategy (REMS). It must be administered in a certified healthcare setting with 2-hour post-dose observation. Home use is not permitted.
• Schedule III EPCS: Any prescription for Spravato in Maine must be transmitted electronically per state EPCS rules.
• Specialty pharmacy dispensing: Spravato is distributed through specialty pharmacies designated by the REMS program.

Because Spravato requires in-office administration, it cannot be prescribed or initiated via standard telehealth. Patients who qualify for Spravato should contact Humana at 1-800-448-6262 to confirm Part D coverage specifics under their plan before starting treatment.

Federal Parity Protections Under CMS 42 CFR Part 422

As a Medicare Advantage plan, Humana must comply with the federal Mental Health Parity and Addiction Equity Act (MHPAEA) as implemented by CMS. This means Humana may not impose quantitative limits (such as visit caps or day limits) or non-quantitative treatment limits (such as prior authorization or step therapy requirements) on mental health benefits. Including depression treatment. That are more restrictive than those applied to comparable medical or surgical benefits.

Importantly, because § 2749-A only covers state-regulated commercial plans, Humana MA members in Maine cannot file a § 2749-A parity complaint with the Maine Bureau of Insurance (BoI). Instead, parity-related grievances are handled through the federal Medicare appeals process and, if needed, a complaint to CMS at 1-800-633-4227.

Prior Authorization: What to Expect Under HPS

Most first-line generic antidepressants (SSRIs, SNRIs, bupropion, mirtazapine) are available at Tier 1. 2 with minimal or no PA under HPS Part D. Step therapy and PA are more commonly required for brand-name agents, Trintellix, Auvelity, and Spravato.

If your prescriber submits a PA request, the typical HPS process is:

1. Prescriber initiates PA: Submit clinical documentation through the HPS provider portal or by calling 1-800-379-0092.
2. Standard review: HPS typically makes a decision within 72 hours (non-urgent) or 24 hours (urgent/expedited).
3. Peer-to-peer (P2P) review: Your prescriber may request a direct conversation with the HPS medical reviewer to discuss clinical rationale.
4. Approval or denial notice: Written notice will state the basis for any denial and your appeal rights.
5. Transition supply: If you are newly enrolled in a Humana plan and are currently taking a non-formulary or PA-required medication, you may be entitled to a temporary transition supply (up to 30 days).

Step Therapy Exception Rights

CMS requires Medicare Advantage plans to grant step therapy exceptions when:

• The required step-therapy drug is contraindicated for your medical condition.
• You have already tried the required drug and it was ineffective or caused an adverse reaction.
• Trying the required drug would cause an adverse reaction based on your clinical history.

If you have previously failed an antidepressant that HPS requires as a step-therapy drug before covering your prescribed medication, document this history with your prescriber and request a step therapy exception when submitting the PA.

Dual-Eligible Members: Medicare and MaineCare (Medicaid)

Some Humana Medicare Advantage members in Maine are also enrolled in MaineCare, Maine’s Medicaid program. These dual-eligible members may have depression medication coverage through both Medicare Part D (HPS formulary) and MaineCare, with coordination rules that affect cost-sharing and formulary access.

If you are dual-eligible and face a coverage gap or denial under HPS, MaineCare may provide supplemental coverage for medications not covered under Part D. Contact Maine DHHS at 1-800-977-6740 or Maine’s State Health Insurance Assistance Program (SHIP) at 1-877-353-3771 for free counseling on dual-eligible benefits coordination.

Medicaid disclaimer: Klarity Health accepts select Medicaid plans. Coverage and eligibility depend on your specific MaineCare plan and state. Contact us to verify MaineCare acceptance before booking.

Federal Medicare Appeals Process

If Humana denies coverage for a depression medication, you have the right to appeal through the Medicare appeals process. The federal appeals path for Medicare Advantage prescription drug (Part D) coverage decisions is:

1. Coverage redetermination: Request a redetermination from Humana within 60 days of the denial. Humana must respond within 7 days (standard) or 72 hours (expedited).
2. Peer-to-peer review: Your prescriber can request a direct clinical review with the plan’s medical director at any stage.
3. Reconsideration by Independent Review Entity (IRE): If Humana upholds the denial, request reconsideration by the independent review organization (Maximus Federal Services, 1-855-887-6668) within 60 days. IRE reviews are conducted by clinicians independent of Humana.
4. Administrative Law Judge (ALJ) hearing: If the IRE upholds the denial and the amount in controversy meets the threshold ($200+ in 2026), you may request an ALJ hearing.
5. Medicare Appeals Council / Federal District Court: Further escalation if needed after ALJ.

For urgent situations involving serious mental health conditions, request expedited reviews at each level. CMS at 1-800-633-4227 can assist with procedural guidance.

Telehealth Depression Treatment Under Medicare Advantage

CMS telehealth flexibilities extended through 2026 allow Medicare Advantage members to receive mental health evaluations, medication management, and therapy via telehealth without geographic restrictions. Humana MA plans in Maine must cover telehealth mental health services consistent with these CMS guidelines.

For depression treatment via telehealth, this means:

• Initial psychiatric evaluation and medication management can be conducted via video or audio-only telehealth.
• Routine medication refills and follow-up for stable depression can often be managed entirely via telehealth.
• Spravato, due to its REMS in-office requirement, cannot be administered via telehealth regardless of CMS flexibilities.

Getting Depression Treatment Through Klarity Health

Klarity Health connects Maine residents with licensed providers who specialize in depression treatment. Our network includes 2,000+ licensed clinicians across all 50 states who can evaluate, diagnose, and manage depression via telehealth. Including medication management for SSRIs, SNRIs, and other non-controlled antidepressants.

Our providers are experienced with insurance prior authorization processes, including HPS Part D PA requirements for brand-name antidepressants. We can assist with clinical documentation to support your PA request.

Ready to get started?
See if your Humana plan may cover depression treatment at Klarity →

Frequently Asked Questions

Does Humana cover antidepressants in Maine?

Humana Medicare Advantage plans in Maine typically cover antidepressants through the Part D prescription drug benefit administered by Humana Pharmacy Solutions (HPS). Generic SSRIs and SNRIs are usually placed at Tier 1. 2 with no or minimal PA required. Brand-name agents such as Trintellix may require step therapy, and specialty medications like Spravato require PA plus REMS enrollment. Coverage details vary by plan; verify your specific formulary at hpshps.com or by calling HPS at 1-800-379-0092.

Does Maine’s mental health parity law (§ 2749-A) protect Humana members?

No. Section 2749-A applies to state-regulated commercial insurance. Humana operates exclusively as a Medicare Advantage plan in Maine, which is regulated by CMS under 42 CFR Part 422, not by Maine state law. Federal MHPAEA parity protections do apply through CMS regulations, but the enforcement mechanism is the federal Medicare appeals process. Not a § 2749-A parity complaint to the Maine Bureau of Insurance.

Does Spravato require EPCS in Maine?

Yes. Spravato (esketamine nasal spray) is classified as a Schedule III controlled substance. Maine’s EPCS mandate covers Schedule II through Schedule V, so any Spravato prescription in Maine must be transmitted electronically. However, because Spravato also requires in-office administration under the REMS program, it cannot be prescribed via standard telehealth regardless of EPCS status.

Are standard antidepressants subject to Maine EPCS?

No. The vast majority of antidepressants. Including all SSRIs, SNRIs, bupropion, mirtazapine, and TCAs. Are non-scheduled drugs. Maine’s EPCS requirement applies only to controlled substances (Schedule II. V). Non-scheduled antidepressants are entirely unaffected by EPCS rules and can be prescribed via telehealth without any EPCS barrier.

What is the step therapy exception for Humana Part D?

CMS requires Medicare Advantage plans to grant step therapy exceptions when the required step drug is contraindicated, has already been tried and failed, or would cause an adverse reaction. If your prescriber wants to start you on a brand-name antidepressant that HPS requires step therapy to access, document prior treatment history and request a step therapy exception with the PA submission.

How do I appeal a Humana depression medication denial in Maine?

Request a coverage redetermination from Humana within 60 days of the denial. If Humana upholds the denial, request reconsideration by the Independent Review Entity (Maximus Federal Services, 1-855-887-6668). Further escalation is available through an ALJ hearing and the Medicare Appeals Council. For procedural guidance, contact CMS at 1-800-633-4227. Note: the Maine Bureau of Insurance (1-800-300-5000) handles commercial plan complaints but does not have jurisdiction over Medicare Advantage coverage disputes.

Key Contacts

• Humana Member Services: 1-800-448-6262
• Humana Pharmacy Solutions (HPS): 1-800-379-0092
• Maine Bureau of Insurance: 1-800-300-5000 (general insurance questions; not MA disputes)
• Maine DHHS (Medicaid/MaineCare): 1-800-977-6740
• Maine SHIP (Medicare counseling, free): 1-877-353-3771
• Maximus IRE (Medicare independent review): 1-855-887-6668
• CMS (Medicare): 1-800-633-4227

Disclaimer: Coverage details described in this guide reflect typical HPS formulary placement and plan design patterns as of 2026 and may not reflect your specific Humana plan’s current benefits. Coverage varies by plan, formulary tier, and individual clinical criteria. Always verify your specific plan’s coverage directly with Humana (1-800-448-6262) or HPS (1-800-379-0092) before scheduling treatment. This content is for informational purposes only and does not constitute medical or legal advice.